Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20715477 | 0.90 | EPHX2 (0.66) | EPHX2CYP2C9CYP2C19THRBKMT2A | |
| SCHEMBL29038558 | 0.89 | EPHX2 (0.64) | EPHX2CYP2C9CYP2C19THRBKMT2A | |
| SCHEMBL25328235 | 0.85 | THRB (0.77) | EPHX2CYP2C9CYP2C19THRBKMT2A | |
| SCHEMBL3819701 | 0.84 | KMT2A (0.71) | EPHX2CYP2C9CYP2C19THRBKMT2A | |
| SCHEMBL1499245 | 0.84 | HTT (0.61) | EPHX2CYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL2933261 | 0.83 | EPHX2 (0.51) | EPHX2CYP2C9CYP2C19THRBKMT2A | |
| SCHEMBL1499572 | 0.83 | RAB9A (0.55) | EPHX2CYP2C9CYP2C19KMT2AMEN1 | |
| SCHEMBL2497123 | 0.83 | THRB (0.68) | EPHX2CYP2C9CYP2C19THRBKMT2A | |
| SCHEMBL1499508 | 0.83 | NAMPT (0.54) | EPHX2CYP2C9CYP2C19KMT2ARAB9A | |
| SCHEMBL5947875 | 0.82 | EPHX2 (1.00) | EPHX2CYP2C9CYP2C19THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324731-B2 | TXNIP-TRX complex inhibitors and methods of using the same | CITY OF HOPE (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200085800-A1 | TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME | CITY OF HOPE | 2020-03-19 | — | — | US | disclosed |
| US-9775843-B2 | Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders | Grünenthal GmbH (DE) | 2017-10-03 | — | — | US | disclosed |
| US-20170273970-A1 | Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders | Grünenthal GmbH (DE) | 2017-09-28 | — | — | US | disclosed |
| WO-2017120355-A1 | DIHYDROQUINOLINES AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2017-07-13 | — | — | WO | disclosed |
| US-20150290203-A1 | TREATMENT AND/OR PROPHYLAXIS OF TSPO MEDIATED DISEASES AND/OR DISORDERS | Grünenthal GmbH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-8084470-B2 | Substituted nicotinamide compounds and uses thereof | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090076086-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| EP-1763350-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006014168-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-02-09 | — | — | WO | disclosed |
| EP-0292990-A1 | 4-Halopyridine-3-carboxamide compounds and herbicidal composition thereof | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273970-A1 | Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders | TSPO, TPMT, HLA-DRB1 | EPHX2 1332/4885CYP2C9 1795/4885CYP2C19 864/4885 |
| US-20090076086-A1 | SUBSTITUTED NICOTINAMIDE COMPOUNDS AND USES THEREOF | NNT, NAMPT, NADK | EPHX2 1049/4885CYP2C9 255/4885CYP2C19 184/4885 |
| US-20150290203-A1 | TREATMENT AND/OR PROPHYLAXIS OF TSPO MEDIATED DISEASES AND/OR DISORDERS | TSPO, TPMT, HLA-DRB1 | EPHX2 1332/4885CYP2C9 1795/4885CYP2C19 864/4885 |
| US-11324731-B2 | TXNIP-TRX complex inhibitors and methods of using the same | TXN, TXN2, TXNRD3 | EPHX2 3048/4885CYP2C9 3860/4885CYP2C19 4444/4885 |
| US-20200085800-A1 | TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME | TXN, TXN2, TXNRD3 | EPHX2 3048/4885CYP2C9 3860/4885CYP2C19 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.